Results 61 to 70 of about 36,269 (231)

A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers

Frontiers in Oncology, 2021
Background: Fibroblast growth factor receptor 2 (FGFR2) is frequently altered in tumors and one of the top therapeutic targets in cholangiocarcinoma (CHOL) with FGFR2 fusions. Although there have been several studies on individual tumors, a comprehensive
Juanni Li, Kuan Hu, Jinzhou Huang, Lei Zhou, Yuanliang Yan, Yuanliang Yan, Zhijie Xu   +6 more
doaj   +1 more source

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

Nature Communications
Fibroblast growth factor receptor (FGFR)−2 can be inhibited by FGFR-selective or non-selective tyrosine kinase inhibitors (TKIs). Selective TKIs are approved for cholangiocarcinoma (CCA) with FGFR2 fusions; however, their application is limited by a ...
Stephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, A. Stahl, Yvonne Rasen, C. Geisler, K. Ruhm, Marion Klaumuenzer, Thales Kronenberger, Stefan A. Laufer, H. Sundberg-Malek, K. Bui, M. Horger, Saskia Biskup, K. Schulze-Osthoff, M. Templin, Nisar P. Malek, Antti Poso, M. Bitzer   +18 more
semanticscholar   +1 more source

FGFR Like1 drives esophageal cancer progression via EMT, PI3K/Akt, and notch signalling: insights from clinical data and next‐generation sequencing analysis

FEBS Open Bio, EarlyView.
Clinical analysis reveals significant dysregulation of FGFRL1 in esophageal cancer (EC) patients. RNAi‐coupled next‐generation sequencing (NGS) and in vitro study reveal FGFRL1‐mediated EC progression via EMT, PI3K/Akt, and Notch pathways. Functional assays confirm its role in tumor growth, migration, and invasion.
Aprajita Srivastava, Anoop Saraya, Deepak Gunjan, Rinu Sharma   +3 more
wiley   +1 more source

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

Cancer Medicine, 2022
This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements.
G. Shi, Xiao-yong Huang, T. Wen, T. Song, M. Kuang, H. Mou, Lequn Bao, Haifeng Zhao, Hong Zhao, Xielin Feng, Bi-xiang Zhang, T. Peng, Yu-Bao Zhang, Xia Li, Hong-sheng Yu, Yu Cao, Lian-Xin Liu, Ti Zhang, Weilin Wang, Jianghua Ran, Ying-Bin Liu, W. Gong, Mingxia Chen, Lian Cao, Yang Luo, Yan V. Wang, Hui Zhou, Guo-huan Yang, Jia Fan, Jian Zhou   +29 more
semanticscholar   +1 more source

A Modular Bioinstructive Platform Reveals Mechanistic Insights into Additive‐Free, Topography‐Driven Osteogenesis

Advanced Healthcare Materials, EarlyView.
Engineered microparticle topographies direct human mesenchymal stem cell osteogenesis without biochemical additives. This osteogenic commitment is driven by canonical Hedgehog signaling and followed by temporal IGF‐II engagement. Two‐photon polymerization demonstrates spatial control, enabling the engineering of topographical gradients that pattern ...
Fatmah I. Ghuloum, Leo A. H. Zeef, Lee A. Stevens, Marco A. N. Domingos, Susan J. Kimber, Mahetab H. Amer   +5 more
wiley   +1 more source

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma

Molecular Cancer Therapeutics, 2020
The fibroblast growth factor receptor (FGFR) signaling pathway is aberrantly activated in approximately 15% to 20% of patients with intrahepatic cholangiocarcinoma.
M. Krook, Alexandria Lenyo, Max Wilberding, H. Barker, Mikayla Dantuono, Kelly M. Bailey, Hui-Zi Chen, J. Reeser, M. Wing, J. Miya, E. Samorodnitsky, Amy M. Smith, T. Dao, Dorrelyn Martin, K. Ciombor, J. Hays, A. Freud, S. Roychowdhury   +17 more
semanticscholar   +1 more source

Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.

The Journal of the National Comprehensive Cancer Network, 2022
Despite advances in cancer therapeutics, pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, with a poor prognosis at time of diagnosis.
Camille Ng, J. Glaspy, Veronica R. Placencio-Hickok, Shant Thomassian, J. Gong, A. Osipov, A. Hendifar, Natalie Moshayedi   +7 more
semanticscholar   +1 more source

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis

Advanced Science, EarlyView.
This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer, Thomas Albrecht, Alphonse Charbel, Michael T. Dill, Carsten Sticht, Carolina De La Torre, Stefan Pusch, Arianeb Mehrabi, Kai Breuhahn, Junfang Ji, Peter Schirmacher, Benjamin Goeppert, Stephanie Roessler   +21 more
wiley   +1 more source

FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway

Cellular Physiology and Biochemistry, 2018
Background/Aims: Fibroblast growth factor receptor 2 (FGFR2) has attracted considerable interest as a therapeutic target in gastric cancer (GC). There is growing evidence to suggest that the bioavailability of the potent pro-tumor function of FGFR2 is ...
Tingting Huang, Dian Liu, Yihua Wang, Piao Li, Li Sun, Huihua Xiong, Yuhong Dai, Man Zou, Xianglin Yuan, Hong  Qiu   +9 more
doaj   +1 more source

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies

Case Reports in Oncology, 2020
Cholangiocarcinoma is a very heterogenous cancer and “target-rich” disease. While the current classifications are based on the anatomic location of these tumors (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer ...
Pashtoon Murtaza Kasi
doaj   +1 more source